Song, 2015 - Google Patents

Small-Molecule Probes for the Modulation of Ligand-Receptor Interactions within the TNF Superfamily

Song, 2015

View PDF
Document ID
2561968691560630904
Author
Song Y
Publication year
Publication venue
J Immunoassay & Immunochemistry

External Links

Snippet

The activation and clonal expansion of T cells requires not just engagement of the T cell receptor (TCR), but also a functionally defined second co-stimulatory signal. Interactions between several co-stimulatory molecules within the tumor necrosis factor (TNF) superfamily …
Continue reading at scholarship.miami.edu (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Similar Documents

Publication Publication Date Title
Bojadzic et al. Toward small-molecule inhibition of protein–protein interactions: General aspects and recent progress in targeting costimulatory and coinhibitory (immune checkpoint) interactions
Song et al. TNF superfamily protein-protein interactions: feasibility of small-molecule modulation
Rauert et al. Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2)
Chen et al. Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?
So et al. Regulation of PI-3-kinase and Akt signaling in T lymphocytes and other cells by TNFR family molecules
Dickens et al. The ‘complexities’ of life and death: death receptor signalling platforms
Jaworski et al. The paracaspase MALT1: biological function and potential for therapeutic inhibition
An et al. Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation
Ware Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways
Roos et al. Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-κB pathway
Brown et al. Differential signaling and tumor necrosis factor receptor–associated factor (Traf) degradation mediated by Cd40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (Lmp1)
Song et al. Small‐molecule modulators of the OX 40–OX40 ligand co‐stimulatory protein–protein interaction
Müller et al. Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization
TW202134216A (en) Inhibitors of hif-2alpha
Zhu et al. Hematopoietic progenitor kinase 1 in tumor immunology: a medicinal chemistry perspective
Wajant et al. Targeting regulatory T cells by addressing tumor necrosis factor and its receptors in allogeneic hematopoietic cell transplantation and cancer
US20220211701A1 (en) Treatment of cancer utilizing an identified adenosine fingerprint
CN110545826A (en) Methods and compositions for using therapeutic T cells in combination with kinase inhibitors
EP3600372A1 (en) Synthekine compositions and methods of use
Bittner et al. Multifaceted death receptor 3 signaling—promoting survival and triggering death
McFarlane et al. Molecular and cellular factors determining the functional pleiotropy of cytokines
Yoo et al. LIGHT (TNFSF14) costimulation enhances myeloid cell activation and antitumor immunity in the setting of PD-1/PD-L1 and TIGIT checkpoint blockade
Salzmann et al. TWEAK inhibits TRAF2-mediated CD40 signaling by destabilization of CD40 signaling complexes
MX2007005378A (en) Polypeptides that bind baff and/or april.
Moriya et al. Structure-Based Development of a Protein–Protein Interaction Inhibitor Targeting Tumor Necrosis Factor Receptor-Associated Factor 6